{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:47Z","timestamp":1782970547667,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171974"],"award-info":[{"award-number":["82171974"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of parathyroid hormone(PTH) analogs alone as compared with the conventional therapy on HypoPTH, and assess its emphasis on patients\u2019 health-related quality of life (HRQoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Database (PubMed, Web of Science, Embase and Cochrane Library) were systematically searched until February 30, 2026. The primary outcomes were serum calcium and serum phosphate, while the secondary outcomes included 24-hour urinary calcium excretion, serum 25(OH)D, serum 1,25-dihydroxyvitamin D, calcium phosphate product, estimated glomerular filtration rate (eGFR), adverse events, and HRQoL. Meta-analysis was conducted using RevMan 5.4 and STATA 17.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies were included. Compared to conventional therapy, PTH analogs therapy showed no difference in serum calcium (MD = -0.02 mmol\/L; 95% CI, -0.14 to 0.11 mmol\/L), serum phosphorus (MD\u00a0=\u00a00.08 mmol\/L; 95% CI, -0.05 to 0.20 mmol\/L) and 24-hour urinary calcium excretion (MD\u00a0=\u00a01.00 mmol; 95% CI, -1.84 to 3.84 mmol). PTH analogs decreased 25(OH) vitamin D, increased 1,25(OH)\n                      <jats:sub>2<\/jats:sub>\n                      vitamin D and eGFR. Additionally, PTH analogs therapy significantly improved HRQoL as measured by the Short Form 36 (SF-36) Health Survey Questionnaire (MD = -7.35; 95% CI, -8.37 to -6.33).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In addition to the comparable control of serum calcium and serum phosphorus levels to conventional therapy, limited data indicate that PTH analogs treatment may be better in regulating the serum vitamin D and maintaining the eGFR for patients with HypoPTH. PTH analogs therapy also improves patients\u2019 HRQoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251089112.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1847971","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:23:35Z","timestamp":1782966215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of parathyroid hormone analogs therapy on hypoparathyroidism: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Siting","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4566","article-title":"Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000549","article-title":"Hypoparathyroidism: update of guidelines from the 2022 International Task Force","volume":"66","author":"Clarke","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4716","article-title":"Management of hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/ec-20-0366","article-title":"Challenges in the management of chronic hypoparathyroidism","volume":"9","author":"Zavatta","year":"2020","journal-title":"Endocr Connect"},{"key":"B5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5114\/pedm.2019.89642","article-title":"Recombinant parathyroid hormone for hypoparathyroidism in children: a narrative review","volume":"25","author":"Dayal","year":"2019","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4274","article-title":"Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: an open-label study","volume":"36","author":"Ish-Shalom","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.276.8.631","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism - results of a short-term randomized crossover trial","volume":"276","author":"Winer","year":"1996","journal-title":"Jama-Journal Am Med Assoc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_340_16","article-title":"Efficacy of teriparatide in patients with hypoparathyroidism: a prospective, open-label study","volume":"21","author":"Upreti","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02577-x","article-title":"Chronic hypoparathyroidism and treatment with teriparatide","volume":"72","author":"Marcucci","year":"2021","journal-title":"Endocrine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1-34) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study (vol 1, pg 275, 2013) [Correction","volume":"2","author":"Mannstadt","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02430","article-title":"Quality of life in hypoparathyroidism improves with rhPTH(1-84) throughout 8 years of therapy","volume":"104","author":"Tabacco","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa490","article-title":"Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1-84)","volume":"105","author":"Chen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.12.001","article-title":"Extended treatment with recombinant human parathyroid hormone (1-84) in adult patients with chronic hypoparathyroidism","volume":"30","author":"Rubin","year":"2024","journal-title":"Endocrine Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/ec-24-0464","article-title":"Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist","volume":"14","author":"Ovize","year":"2025","journal-title":"Endocr Connect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae121","article-title":"An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism","volume":"109","author":"Takacs","year":"2024","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1847971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:23:36Z","timestamp":1782966216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1847971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":24,"alternative-id":["10.3389\/fendo.2026.1847971"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1847971","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1847971"}}